Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.

Granules India seeks first mover advantage | Photo Credit: The Hindu Generic drugmaker Granules India has filed a Paragraph IV certification with the U.S. Food and Drug Administration (U.S. FDA)…